Department of Gastroenterology, Huzhou Central Hospital, Huzhou, Zhejiang Province, China.
Huzhou Key Laboratory of Molecular Medicine, Huzhou Central Hospital, 198 Hongqi Road, Huzhou, Zhejiang Province, China.
J Glob Antimicrob Resist. 2018 Jun;13:174-179. doi: 10.1016/j.jgar.2017.12.018. Epub 2018 Feb 11.
A personalised diagnosis kit for Helicobacter pylori that employs visual gene chip technology for the simultaneous detection of CYP2C19 polymorphisms and clarithromycin/levofloxacin antibiotic resistance was evaluated.
Gastric antrum mucosa biopsy specimens of 394 patients were tested using the kit. DNA sequencing and antibiotic susceptibility testing of the H. pylori were also performed.
In total, 267 (67.8%) of the 394 specimens were positive for H. pylori using the kit and DNA sequencing, and 136 (34.5%) were positive by culturing. For human CYP2C19 and the bacterial 23S rRNA and gyrA genes, the concordance rates were 92.4% (364/394), 96.6% (258/267) and 97.0% (259/267) between the kit and DNA sequencing results, respectively. For clarithromycin and levofloxacin resistance, the concordance rates were 90.4% (123/136) and 81.6% (111/136) between the kit and antibiotic susceptibility testing results.
The personalised diagnosis kit for H. pylori provides useful information for the choice of proton pump inhibitor and antibiotic in combination therapy.
采用可视化基因芯片技术，同时检测 CYP2C19 多态性和克拉霉素/左氧氟沙星抗生素耐药性，评估一种用于幽门螺杆菌的个体化诊断试剂盒。
采用试剂盒检测 394 例患者的胃窦黏膜活检标本。还对 H. pylori 进行 DNA 测序和抗生素药敏试验。
使用试剂盒和 DNA 测序，总共 394 个标本中有 267 个（67.8%）为 H. pylori 阳性，培养阳性率为 136 个（34.5%）。对于人 CYP2C19 和细菌 23S rRNA 和 gyrA 基因，试剂盒与 DNA 测序结果的一致性率分别为 92.4%（364/394）、96.6%（258/267）和 97.0%（259/267）。对于克拉霉素和左氧氟沙星耐药性，试剂盒与抗生素药敏试验结果的一致性率分别为 90.4%（123/136）和 81.6%（111/136）。
用于 H. pylori 的个体化诊断试剂盒为质子泵抑制剂和抗生素联合治疗方案的选择提供了有用的信息。
